Pharmasset - Poised to Deliver the Best Oral Option Against HCV Infection
Pharmasset (VRUS) has created immense value for its shareholders by promising the best treatment options in HCV on its own or through collaborations. Emerging markets have more HCV pts than US and EU and we expect the new drugs and companies to target these markets in the future. Competitor’s data read out does not threaten VRUS endeavors of developing IFN-free treatment option. For more detail, please read our note released on 28th July on Pharmasset titled “Poised to Deliver the Best Oral Option Against HCV Infection”.
COMPANIES MENTIONED
Pharmasset, VRUS
Pharmasset, VRUS
